| [1] |
Paluch-Shimon S, Cardoso F, Partridge AH, et al. ESO-ESMO 4th international consensus guidelines for breast cancer in young women (BCY4) [J]. Ann Oncol, 2020, 31(6): 674-696.
|
| [2] |
Azim HA Jr, Brohée S, Peccatori FA, et al. Biology of breast cancer during pregnancy using genomic profiling[J]. Endocr Relat Cancer, 2014，21(4): 545-554.
|
| [3] |
Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer[J]. Nature, 2012, 486(7403): 400-404.
|
| [4] |
Azim HA Jr, Nguyen B, Brohée S, et al. Genomic aberrations in young and elderly breast cancer patients [J]. BMC Med, 2015, 13: 266.
|
| [5] |
Liao S, Hartmaier RJ, McGuire KP, et al. The molecular landscape of premenopausal breast cancer[J]. Breast Cancer Res, 2015, 17: 104.
|
| [6] |
Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2，433 breast cancers refines their genomic and transcriptomic landscapes[J]. Nat Commun, 2016, 7: 11 479.
|
| [7] |
Azim HA Jr, Michiels S, Bedard PL, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling[J]. Clin Cancer Res, 2012, 18(5): 1341-1351.
|
| [8] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015，65(1):5-29.
|
| [9] |
Li N, Wang X, Zhang H, et al. Young male breast cancer, a small crowd, the survival, and prognosis? A population-based study[J]. Medicine (Baltimore), 2018, 97(40): e12686.
|
| [10] |
Heymann S, Delaloge S, Rahal A, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome[J]. Radiat Oncol, 2010, 5: 104.
|
| [11] |
Ashworth A, Kong W, Whelan T, et al. A population-based study of the fractionation of postlumpectomy breast radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2013, 86(1): 51-57.
|
| [12] |
Smith BD, Bellon JR, Blitzblau R, et al. Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline[J]. Pract Radiat Oncol, 2018, 8(3): 145-152.
|
| [13] |
Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer[J]. N Engl J Med, 2018, 379(2): 122-137.
|
| [14] |
Pagani O, Francis PA, Fleming GF, et al. Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: results from TEXT and SOFT[J]. J Clin Oncol, 2020, 38(12): 1293-1303.
|
| [15] |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J]. 中国癌症杂志，2019, 29(8): 609-679.
|
| [16] |
中国抗癌协会乳腺癌专业委员会. 中国早期乳腺癌卵巢功能抑制临床应用专家共识(2018年版)[J]．中国癌症杂志，2018，28(11):871-880.
|
| [17] |
Regan MM, Walley BA, Francis PA, et al. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT[J]. Ann Oncol, 2017, 28(9): 2225-2232.
|
| [18] |
Lambertini M, Moore HCF, Leonard RCF, et al. Gonadotropinreleasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data[J]. J Clin Oncol, 2018, 36(19): 1981-1990.
|
| [19] |
Chen H, Xiao L, Li J, et al. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women[J]. Cochrane Database Syst Rev, 2019，3(3): CD008018.
|
| [20] |
Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy[J]. N Engl J Med, 2015, 372(10): 923-932.
|
| [21] |
Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies[J]. Ann Oncol, 2015, 26(12): 2408-2419.
|
| [22] |
Pan H, Gray R, Braybrooke J, et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years[J]. N Engl J Med, 2017，377(19):1836-1846.
|
| [23] |
Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869): 805-816.
|
| [24] |
Gray RG, Rea D, Handley K, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer[J]. J Clin Oncol, 2013, 31(15 suppl): 5.
|
| [25] |
Cluze C, Rey D, Huiart L, et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time[J]. Ann Oncol, 2012, 23(4): 882-890.
|
| [26] |
Llarena NC, Estevez SL, Tucker SL, et al. Impact of fertility concerns on tamoxifen initiation and persistence[J]. J Natl Cancer Inst, 2015, 107(10): djv202.
|
| [27] |
Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer[J]. Breast Cancer Res Treat, 2011, 126(2): 529-537.
|
| [28] |
Murphy CC, Bartholomew LK, Carpentier MY, et al. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review[J]. Breast Cancer Res Treat, 2012, 134(2): 459-478.
|
| [29] |
Boccardo F, Rubagotti A, Amoroso D, et al. Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre-and perimenopausal breast cancer patients[J]. Cancer Chemother Pharmacol, 1999, 43(6): 461-466.
|
| [30] |
Noguchi S, Kim HJ, Jesena A, et al. Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer [J]. Breast Cancer, 2016, 23(5): 771-779.
|
| [31] |
范蕾，YEH Yu-Chen, 杜芬，等. 中国绝经前激素受体阳性乳腺癌辅助内分泌治疗最小成本分析[J]. 中国药物经济学，2020, 15(4):5-10.
|
| [32] |
Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression [J]. J Clin Oncol, 2016, 34(14): 1689-1701.
|
| [33] |
Yeo W, Ueno T, Lin CH, et al. Treating HR+/HER2- breast cancer in premenopausal asian women: Asian breast cancer cooperative group 2019 consensus and position on ovarian suppression [J]. Breast Cancer Res Treat, 2019, 177(3): 549-559.
|
| [34] |
Partridge AH, Gelber S, Piccart-Gebhart MJ, et al. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial[J]. J Clin Oncol, 2013, 31(21): 2692-2698.
|
| [35] |
Earl HM, Hiller L, Vallier AL, et al. 6 versus 12 months of adjuvant trastuzumab for HER-2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial[J]. Lancet, 2019, 393(10 191): 2599-2612.
|
| [36] |
Inno A, Barni S, Ghidini A, et al. One year versus a shorter duration of adjuvant trastuzumab for HER-2-positive early breast cancer: a systematic review and meta-analysis[J]. Breast Cancer Res Treat, 2019, 173(2): 247-254.
|
| [37] |
Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER-2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol, 2016, 17(6):791-800.
|
| [38] |
von Minckwitz G, Procter M, de Azambuja E，et al. Adjuvant pertuzumab and trastuzumab in early HER-2-positive breast cancer[J]. N Engl J Med, 2017, 377(2): 122-131.
|
| [39] |
von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER-2-positive breast cancer[J]. N Engl J Med, 2019, 380(7): 617-628.
|
| [40] |
Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER-2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(12):1688-1700.
|
| [41] |
Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation[J]. N Engl J Med, 2017, 377(17):1700.
|
| [42] |
Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation[J]. N Engl J Med, 2018, 379(8): 753-763.
|
| [43] |
Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis[J]. Int J Cancer, 2015, 136(3): 668-677.
|
| [44] |
Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis[J]. BMJ, 2014, 348: g226.
|
| [45] |
Kiely BE, Jenkins MA, McKinley JM, et al. Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other highrisk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)[J]. Breast Cancer Res Treat, 2010, 120(3): 715-723.
|